Top modalities to prioritize by situation
This is not a universal ranked list. The best modality depends on stage and resectability, ECOG performance status, molecular and germline biomarkers, organ function, and the patient's goals. Use this as an orientation map — your oncology team determines what applies to your specific case. This page is a decision-support checklist, not medical advice.
If the tumor is resectable — or converted to resectable after neoadjuvant therapy — surgery at a high-volume pancreatic cancer center is the only potentially curative option. Volume-outcome data for pancreatectomy is among the strongest in surgical oncology: complication rates and mortality are significantly lower at centers performing many cases per year. Surgery should be paired with perioperative or adjuvant chemotherapy (mFOLFIRINOX or gemcitabine + capecitabine, based on current evidence). Ask for a surgical second opinion if resectability is uncertain — assessments can differ between institutions.
For metastatic or locally advanced disease in patients with adequate performance status, systemic chemotherapy is the primary treatment modality. Standard first-line options:
Modified FOLFIRINOX (mFOLFIRINOX) — first-line standard for ECOG 0–1; reduces toxicity of original FOLFIRINOX while maintaining efficacy. NALIRIFOX (liposomal irinotecan + 5-FU/LV + oxaliplatin) — an emerging first-line option with supporting trial data (NAPOLI-3) appropriate in selected patients. Gemcitabine + nab-paclitaxel — an established first-line alternative, often preferred when FOLFIRINOX tolerability is a concern. Gemcitabine alone — appropriate for frailer patients (ECOG 2+) or significant comorbidity. Performance status, bilirubin, renal function, and prior neuropathy all influence regimen selection.
For borderline-resectable or locally advanced disease, systemic chemotherapy (and sometimes radiation) given before surgery — neoadjuvant therapy — can shrink the tumor enough to achieve surgical margins or make surgery feasible. After a defined treatment course, the tumor is restaged and resectability is reassessed. Not all patients convert to resectable, but this is a critical pathway to evaluate before committing to a surgery-first or systemic-only plan. Ask your oncology and surgical teams explicitly whether neoadjuvant sequencing applies to your staging.
Comprehensive molecular and germline profiling should be completed early — results can change the treatment plan and unlock targeted therapy or trial eligibility. Key actionable findings in pancreatic cancer:
BRCA1/2, PALB2, ATM (HRR pathway) — confers platinum sensitivity; maintenance olaparib (PARP inhibitor) is FDA-approved for germline BRCA1/2 after platinum response. MSI-H / dMMR — rare (~1–2%) but highly actionable; pembrolizumab is FDA tumor-agnostic approved. NTRK fusions — entrectinib or larotrectinib available tumor-agnostically. NRG1 fusions, FGFR alterations, other rare fusions — emerging trial options. Ask about the PanCAN Know Your Tumor program for coordinated profiling and trial matching.
In pancreatic cancer, clinical trials should be explored at every line of therapy — not only after standard options have failed. Trials provide access to KRAS-targeted agents, novel immunotherapy combinations, adoptive cell therapies, and other modalities only available on protocol. Molecular profiling results determine eligibility for biomarker-matched trials. Ask your oncology team to search ClinicalTrials.gov and contact PanCAN Patient Services for trial matching at any stage of disease.
Stereotactic body radiation therapy (SBRT) or conventionally fractionated chemoradiation may be appropriate for selected locally advanced or borderline-resectable tumors — typically after systemic chemotherapy has stabilized disease, as part of a neoadjuvant/conversion strategy, or for local symptom control (pain, obstruction). The role of radiation in pancreatic cancer is debated and institution-dependent; it is not a default option for all stages. A radiation oncology consultation alongside your medical oncology team is the right way to evaluate whether and when this applies.
Palliative care is not end-of-life care — it is specialized support that runs in parallel with active treatment to improve quality of life and manage symptoms. Key components: pain management (including celiac plexus neurolysis or block for refractory abdominal pain); biliary stenting (ERCP or percutaneous) for obstruction/jaundice; pancreatic enzyme replacement (PERT) for exocrine insufficiency and malabsorption; nutrition support from a registered oncology dietitian (cachexia is a major treatment-limiting concern); and psychosocial/mental health support. Early palliative care referral is associated with better quality of life and, in some settings, improved survival. Ask for a referral from the start, not just at the end.
Integrative and holistic approaches (nutrition protocols, supplements, mind-body practices, acupuncture, herbal products, and similar) may have a role as supportive care — but only after review by your oncology team and pharmacist for drug interactions and safety during active treatment. No adjunct or holistic modality is a substitute for staging, surgery, chemotherapy, or clinical trials. Some supplements alter chemotherapy metabolism through CYP450 pathways; some herbal products are hepatotoxic or nephrotoxic. Always disclose every supplement, herbal product, and over-the-counter agent to your oncologist and pharmacist. Integrative medicine consultations at NCI-designated cancer centers can help evaluate options safely within your treatment plan.
- →If potentially resectable: get a pancreatic surgeon consultation at a high-volume center immediately — resectability assessment determines the entire treatment pathway and can differ significantly between institutions.
- →If metastatic and fit (ECOG 0–1): discuss the best systemic regimen (mFOLFIRINOX, NALIRIFOX, or gemcitabine + nab-paclitaxel) and search for open clinical trials now — not after first-line progression.
- →If BRCA/PALB2/HRR mutation identified: ask specifically about platinum-containing regimens and PARP inhibitor maintenance eligibility — this changes the treatment plan.
- →If frail, obstructed, or significantly cachectic: stabilize first — address bile flow (stent if needed), pain, and nutrition before intensifying systemic treatment. Palliative care team involvement is essential from the start.
What to gather before your oncology meeting
Bring or request all of the following before your first oncology decision meeting. Incomplete information can delay staging, treatment access, and trial eligibility.
- Exact pathology report — cell type (ductal adenocarcinoma, IPMN-associated, acinar, etc.), grade, margins if surgical specimen
- Stage & resectability assessment — resectable, borderline-resectable, locally advanced, or metastatic; radiologist and surgical team input needed
- CT abdomen/pelvis with contrast — triple-phase pancreatic protocol preferred; also MRI liver and/or PET-CT if available
- CA 19-9 baseline — not diagnostic alone (can be falsely normal or elevated); useful for tracking if tumor is secretor
- Liver and kidney function labs — bilirubin, ALT, AST, ALP, creatinine/eGFR — affects chemo dosing and eligibility
- ECOG / performance status — your oncologist should assess this formally; it determines which regimens are feasible
- Diabetes, cachexia & weight loss — new-onset diabetes is common; weight loss percentage over prior 3–6 months; exocrine insufficiency history
- Full current medication list — including supplements, OTC, herbal, cannabis — drug interactions with chemo are common and serious
- Prior treatments — any prior chemotherapy, radiation, surgery, or investigational treatment and outcomes
- Somatic (tumor) molecular testing — NGS on tumor tissue or cell-free DNA (liquid biopsy); look for KRAS, TP53, SMAD4, CDKN2A, BRCA1/2, PALB2, ATM, NTRK fusions, MSI-H/dMMR, TMB, NRG1 fusions
- Germline (hereditary) testing — BRCA1/2, PALB2, ATM, BRCA-panel; relevant for PARP inhibitor eligibility and family implications
Conventional treatment options to discuss
These are established or guideline-recommended approaches. Which apply depends on stage, performance status, and molecular profile — your oncologist will determine appropriateness.
Whipple procedure (pancreaticoduodenectomy), distal pancreatectomy, or total pancreatectomy depending on tumor location. Only ~20% of patients present with resectable disease. Borderline-resectable tumors may be downstaged with neoadjuvant chemotherapy first. Ask whether high-volume surgical center referral is indicated — volume-outcome relationship is strong for pancreatectomy.
Combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin. Used in metastatic and locally advanced settings; also neoadjuvant and adjuvant. Generally reserved for patients with good performance status (ECOG 0–1). Modified FOLFIRINOX (mFOLFIRINOX) reduces toxicity. Ask your oncologist whether this regimen fits your performance status and organ function.
Gemcitabine combined with albumin-bound paclitaxel (Abraxane). An alternative first-line regimen, especially for patients who may not tolerate FOLFIRINOX. Also used in second-line and adjuvant settings. Ask about predicted tolerability based on your labs and performance status.
Stereotactic body radiation therapy (SBRT) or conventionally fractionated chemoradiation may be considered for locally advanced, unresectable tumors after systemic therapy stabilizes disease, or for borderline-resectable cases. Role in pancreatic cancer is debated; ask your team whether a radiation oncology consultation is appropriate.
Palliative care is not end-of-life care — it is specialized support alongside any active treatment. Includes pain management, nutrition counseling, pancreatic enzyme replacement (PERT) for exocrine insufficiency, biliary stenting for jaundice/obstruction, anti-nausea support, and mental health/social work. Early palliative care referral is associated with better quality of life and can extend survival in some settings. Ask for a palliative care referral from day one.
Biliary obstruction often requires stenting (endoscopic ERCP or percutaneous). Celiac plexus neurolysis or block for refractory pain. PERT (pancreatic enzyme replacement therapy) for malabsorption. Registered dietitian consultation for cachexia and weight loss. Diabetes management post-surgery or with pancreatic involvement. These require dedicated specialist coordination.
Pancreatic cancer has few standard second-line options. Clinical trials should be considered at every line of therapy, not just as a last resort. Search NCI trial finder and ClinicalTrials.gov. PanCAN's Patient Services can help identify appropriate trials. Ask your oncologist whether molecular profiling results open trial-specific eligibility.
Source: NCI Pancreatic Cancer Treatment PDQ (HP) · NCI PDQ (Patient)
Molecular testing & targeted therapy leads
Molecular profiling is increasingly essential. A matching biomarker can unlock a trial or approved agent. Request testing early — tissue availability can be limited.
Patients with germline BRCA1/2 mutations who respond to platinum-based chemotherapy may be eligible for maintenance olaparib (Lynparza) — FDA-approved for this indication. PALB2 and ATM mutations may also confer platinum sensitivity. Ask your oncologist about germline panel testing and whether olaparib maintenance is appropriate after front-line platinum response.
Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) tumors respond to pembrolizumab (Keytruda) — FDA tumor-agnostic approval. Relevant if your tumor tests positive; uncommon in pancreatic cancer (~1–2% of cases) but extremely important to identify. High TMB may also support pembrolizumab eligibility. Verify with your oncologist based on actual biomarker results.
NTRK gene fusions are rare in pancreatic cancer but qualify for entrectinib or larotrectinib (FDA tumor-agnostic). NRG1 fusions and FGFR alterations have emerging targeted options in trials. These are only relevant if molecular profiling identifies them — do not pursue without confirmed result.
KRAS mutations (~90% of pancreatic adenocarcinomas) are now actionable targets in trials — KRAS G12C inhibitors (sotorasib, adagrasib) and G12D/G12V agents are in development. TCR-based T-cell receptor therapies targeting KRAS-mutant epitopes are in early trials. None are approved for pancreatic cancer; enrollment in a clinical trial is required. Ask your oncologist or check NCT04146298 and related listings.
PanCAN's Know Your Tumor program coordinates molecular profiling and matches results to trials and targeted options. A second opinion at a high-volume pancreatic cancer center (MD Anderson, Memorial Sloan Kettering, Mayo Clinic, Johns Hopkins, etc.) is strongly encouraged before committing to a treatment plan — surgical resectability assessments in particular can differ between institutions.
Options from research leads — evidence tiered
The following options range from adjunct interventions with some clinical interest to preclinical-only agents to items that require strong safety warnings. None of these are proven to cure pancreatic cancer. All must be discussed with your oncology team before use — drug interactions, metabolic effects, and liver/kidney impacts are real concerns during active treatment.
High-dose intravenous ascorbate (not oral vitamin C) has been studied as an adjunct to chemotherapy in several small trials and case series. Proposed mechanisms include pro-oxidant effects at pharmacological plasma concentrations and possible sensitization to chemotherapy. It is not a proven cancer treatment, but some oncology-integrated practices offer it under supervision alongside standard care.
Extracorporeal blood ozone oxygenation (EBOO/EEBO) involves ozonating blood outside the body. Deuterium-depleted water (DDW) is water with reduced deuterium content, marketed as anti-cancer. Human evidence for either in pancreatic cancer is extremely limited or absent at the clinical trial level. If considering, discuss with your oncologist and disclose to your treatment team. Potential concerns include electrolyte and hydration effects.
Some researchers hypothesize that ketogenic diets may reduce glucose availability to tumors ("Warburg effect"), and water fasting may enhance chemotherapy tolerance in some studies. However, pancreatic cancer is associated with cachexia (severe muscle/weight loss), exocrine insufficiency (fat malabsorption), and often new-onset or worsening diabetes — making aggressive caloric restriction or high-fat diets potentially harmful. Discuss any dietary intervention with a registered oncology dietitian before changing your diet during active treatment.
6-Diazo-5-oxo-L-norleucine (DON) and its prodrug analogs are being investigated as glutamine pathway inhibitors in pancreatic cancer trials. Pancreatic ductal adenocarcinoma is highly glutamine-dependent. This is investigational research — DON is not commercially available and is not for self-administration. If interested, look for open trials through ClinicalTrials.gov.
Cannabis and cannabinoid preparations are used by many cancer patients for symptom management: pain, appetite stimulation, nausea, sleep, and anxiety. Clinical evidence supports cannabinoids for chemotherapy-induced nausea and pain in specific contexts. RSO is a high-potency cannabis extract; evidence for anti-cancer activity in humans is absent at the clinical trial level. Preclinical data exists but does not translate to human proof of efficacy as a cancer treatment.
Hydrogen peroxide baths or topical applications have circulated in alternative health communities as cancer treatments. There is no meaningful clinical oncology evidence supporting this use for pancreatic cancer or any cancer.
Fenbendazole is a veterinary anthelmintic (dewormer). Anecdotal case reports — most prominently a South Korean patient narrative — have generated substantial online interest in fenbendazole as a cancer treatment. Proposed mechanisms involve microtubule disruption similar to vinca alkaloids. No human clinical trials demonstrating efficacy in pancreatic cancer or any cancer have been completed.
Ivermectin has preclinical data showing antiproliferative effects in certain cancer cell lines. Some researchers have proposed it as a drug-repurposing candidate. No human clinical trial evidence demonstrates efficacy in pancreatic cancer. Multiple ongoing or recently completed small trials exist but results are preliminary and inconclusive.
Hydroxychloroquine inhibits autophagy — a survival mechanism heavily relied upon by pancreatic cancer cells. It has been studied in combination with chemotherapy in pancreatic cancer trials. Some small trials showed signal; larger definitive trials have been mixed. It is being studied in combination regimens. Not standard of care; discuss trial eligibility.
Methylene blue has proposed mechanisms involving mitochondrial function, redox signaling, and photodynamic therapy sensitization. Preclinical cancer data exists; clinical oncology evidence is minimal. Used medically for methemoglobinemia (FDA-approved indication) and in some neurology contexts. Not a standard or validated cancer therapy.
Dandelion root extract has been studied in cell culture and some animal models for anti-cancer properties, including apoptosis induction in cancer cell lines. There is no human clinical trial evidence in pancreatic cancer. This is early-stage preclinical research. Dandelion is generally considered safe as a food/tea; supplemental extracts can interact with diuretics and blood thinners. Disclose to your oncology team.
Chlorine dioxide (also marketed as "Miracle Mineral Solution" or MMS) has been promoted in alternative health communities as a cancer treatment among many other claimed uses.
Histotripsy uses focused ultrasound to mechanically destroy tumor tissue without heat, via controlled cavitation. The Edison Histotripsy System received FDA clearance for soft tissue destruction in liver tumors. It is being studied in clinical trials for pancreatic cancer, including for local tumor ablation and potential immune stimulation effects. It is not a general cure for pancreatic cancer and is not widely available.
Ask your team: Are any liver metastases or locally accessible pancreatic lesions candidates for a histotripsy trial? What is the nearest center with this capability?
N-803 (nogapendekin alfa inbakicept, brand Anktiva) is an IL-15 superagonist complex approved by FDA for BCG-unresponsive non-muscle-invasive bladder cancer. It is being studied in trials for other solid tumors due to its NK cell and T cell activating properties. There is no pancreatic cancer approval; this is a signal to discuss with your oncologist in the context of investigational trials. Do not extrapolate bladder cancer data to pancreatic cancer.
Dostarlimab (Jemperli) produced dramatic complete responses in a small trial of dMMR/MSI-H rectal cancer — generating substantial media coverage. This result is highly specific to dMMR/MSI-H tumors and is not generalizable to pancreatic cancer or MSS tumors. In MSS (microsatellite-stable) pancreatic cancer — the vast majority — checkpoint inhibitors have not shown meaningful benefit in trials to date. If your tumor tests MSI-H or dMMR, discuss pembrolizumab or dostarlimab eligibility. If MSS, do not expect the rectal cancer outcomes to transfer.
Certain bacteria, including engineered strains, have been studied as anti-tumor agents due to their ability to colonize hypoxic tumor microenvironments. Ewingella americana has appeared in some basic research contexts. This is early-stage research with no clinical trial data establishing safety or efficacy in humans with pancreatic cancer. Research watchlist only — do not self-administer any bacterial preparation.
Melittin, the primary active component of bee venom, has demonstrated cytotoxic effects in cancer cell lines in laboratory studies, including some pancreatic cancer models. No human clinical trials have established safety or efficacy. Anaphylaxis risk from bee venom is a serious concern. Research watchlist only.
Iron-based metal-organic framework nanoparticles are being studied as drug delivery vehicles and ferroptosis inducers in cancer research. Promising early laboratory data in several tumor types; no clinical-stage trials in pancreatic cancer established. Research watchlist only.
Researchers have explored whether thermogenic (beige/brown) adipose tissue near tumors can deprive cancer cells of metabolic resources and activate immune responses. Very early stage. Not a clinical option. Research watchlist only.
Antineoplastons are peptides and amino acid derivatives developed by Dr. Stanislaw Burzynski. The clinic has operated under clinical trial protocols for decades under FDA oversight, primarily for brain tumors. Evidence of efficacy in pancreatic cancer is not established. The treatment is controversial, with significant regulatory and scientific debate over the decades. If considering, discuss with your oncologist. Any enrollment should be through a registered and currently open clinical trial, reviewed by a knowledgeable oncology team.
Needle-track seeding (peritoneal seeding along the biopsy needle path) is a theoretically possible complication of percutaneous biopsy that has been occasionally reported. The approach used — EUS-guided (endoscopic ultrasound), percutaneous CT-guided, or surgical biopsy — may affect this risk profile. This concern does not mean biopsy should be avoided. Tissue biopsy and pathology are generally necessary for diagnosis, molecular testing, and clinical trial eligibility. Ask your interventional radiologist or gastroenterologist about the preferred biopsy route and associated risk in your specific case.
Gemcitabine + cisplatin is an established combination in oncology, but it is not a generic first-line regimen for all pancreatic cancer patients. It is not interchangeable with standard first-line options without a specific clinical rationale.
The broadly accepted standard first-line regimens for metastatic or locally advanced pancreatic adenocarcinoma are FOLFIRINOX (or modified FOLFIRINOX) and gemcitabine + nab-paclitaxel (Abraxane). Gemcitabine alone remains an option for patients who cannot tolerate combination regimens. These are the regimens supported by the largest randomized trial evidence in unselected pancreatic cancer populations.
Gemcitabine + cisplatin is used primarily in a specific molecular context: patients with germline or somatic BRCA1, BRCA2, or PALB2 mutations, other homologous recombination repair (HRR) pathway defects, or a documented history of platinum sensitivity. In these patients, the tumor's impaired ability to repair platinum-induced DNA damage may make cisplatin-containing regimens more effective. Outside of this context, the evidence base for preferring gemcitabine + cisplatin over standard regimens in pancreatic cancer is limited.
This is not a short, self-contained course: like all systemic chemotherapy for advanced pancreatic cancer, gemcitabine + cisplatin involves ongoing cycles, requires regular labs and monitoring (including renal function, given cisplatin nephrotoxicity), and carries meaningful toxicity including nausea, myelosuppression, and cumulative kidney and hearing effects. It is not one-and-done.
Germline and tumor genomic testing are required to determine whether this regimen is appropriate for a given patient. If testing has not been completed, that should be the first step before committing to a cisplatin-containing regimen.
Ask the oncology team: What specific mutation or clinical finding (BRCA1, BRCA2, PALB2, other HRR defect, or documented platinum sensitivity) supports choosing gemcitabine + cisplatin over FOLFIRINOX or gemcitabine + nab-paclitaxel in this case? Has germline and/or somatic molecular testing been completed and reviewed?
References: NCI PDQ: Pancreatic Cancer Treatment (Patient) — NCI PDQ: Pancreatic Cancer Treatment (Health Professional) — NCI: Gemcitabine + Cisplatin combination — NCI: Drugs approved for pancreatic cancer
Questions to ask your oncology team
These are practical, direct questions to bring to your next appointment. Use this list as a starting point — write your own additions based on your specific situation.
- 1.What is the exact diagnosis — cell type, grade, and stage? Is the tumor resectable, borderline-resectable, locally advanced, or metastatic?
- 2.Has a tumor board or multidisciplinary team reviewed my case? If not, can one be convened?
- 3.Has somatic (tumor) molecular profiling been ordered? Which platform? What are the results, and do any mutations open targeted therapy or trial access?
- 4.Has germline (hereditary) genetic testing been done or ordered? What are the implications if BRCA1/2, PALB2, or ATM alterations are found?
- 5.What is my ECOG performance status? Which first-line regimens are appropriate given my labs and performance status — FOLFIRINOX or gemcitabine/nab-paclitaxel?
- 6.Are there any open clinical trials I qualify for — either now or after first-line therapy? Can we search ClinicalTrials.gov and PanCAN's patient services together?
- 7.Should I get a second opinion at a high-volume pancreatic cancer center before committing to a plan? Can your team help with the referral?
- 8.Can I be enrolled in PanCAN's Know Your Tumor program?
- 9.Is there a palliative care specialist, oncology dietitian, and social worker I should see alongside my treatment?
- 10.Is there a biliary obstruction that needs stenting? Do I have exocrine insufficiency needing pancreatic enzyme replacement (PERT)?
- 11.I am interested in [specific adjunct, e.g., IV vitamin C / ketogenic diet / supplement] — can you review whether it is safe to use alongside my treatment, and whether it could interfere with chemotherapy or labs?
- 12.What is the expected treatment schedule, and what side effects should I prepare for? When should I call or go to the ER vs. manage symptoms at home?
- 13.What are the criteria for evaluating whether this treatment is working? What happens if it stops working?
- 14.Has biopsy been done — and if so, what route was used? Is there any concern about seeding? Do we have enough tissue for repeat molecular testing if needed?
- 15.If gemcitabine + cisplatin is being recommended: what specific mutation (BRCA1, BRCA2, PALB2, or other HRR defect) or clinical platinum-sensitivity finding supports choosing cisplatin over FOLFIRINOX or gemcitabine + nab-paclitaxel? Has germline and/or tumor molecular testing been completed?
Sources & citations
- NCI PDQ: Pancreatic Cancer Treatment (Patient version) — comprehensive NCI overview of pancreatic cancer treatment options
- NCI PDQ: Pancreatic Cancer Treatment (Health Professional version) — detailed clinical evidence summaries
- NCI Clinical Trials: Pancreatic Cancer — search for open trials by disease
- PanCAN Know Your Tumor Program — molecular profiling coordination and trial matching for pancreatic cancer patients
- PanCAN: Pancreatic Cancer Treatment Types — overview of surgery, chemotherapy, radiation, and supportive care options
- ASCO Guideline: Metastatic Pancreatic Cancer (JCO 2016) — American Society of Clinical Oncology clinical practice guideline for metastatic pancreatic cancer systemic therapy
- NCI PDQ: High-Dose Vitamin C (Patient) — evidence summary for IV ascorbate in cancer
- NCI PDQ: High-Dose Vitamin C (HP) — clinical evidence detail for IV ascorbate
- NCI PDQ: Cannabis and Cannabinoids (HP) — evidence summary for cannabis in symptom management
- LiverTox: Fenbendazole — hepatotoxicity profile and drug information
- American Cancer Society: What to Know About Fenbendazole — overview of current evidence and cautions
- FDA: Adverse Events Associated with Extra-Label Use of Fenbendazole
- FDA: Warning on Miracle Mineral Solution (Chlorine Dioxide) — safety alert for MMS/ClO₂
- HistoSonics: FDA Clearance of Edison Histotripsy System — liver tumor tissue destruction device
- ClinicalTrials.gov NCT04146298 — example KRAS-targeted immunotherapy trial; verify current status
- NCI: Gemcitabine + Cisplatin combination
- NCI: Drugs Approved for Pancreatic Cancer — full list of FDA-approved drugs and combinations for pancreatic cancer